Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders

• US 20050095228A1
• Filed: 07/01/2004
• Published: 05/05/2005
• Est. Priority Date: 12/07/2001
• Status: Abandoned Application

• Current Assignee: Lorem Vascular Pte. Ltd.
• Original Assignee: Lorem Vascular Pte. Ltd.
• Inventors: Fraser, John K., Hedrick, Marc H., Daniels, Eric
• Application Number:
  US10/884,871
• Publication Number:
  US 20050095228A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A61K 35/28 Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• CPC Class Codes: A61K 35/44 Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61L 2300/64 Animal cells
• CPC Class Codes: A61L 2430/00 Materials or treatment for tissue regeneration
• CPC Class Codes: A61L 2430/36 for embolization or occlusion, e.g. vaso-occlusive compositions or devices artificial blood vessels A61L27/507
• CPC Class Codes: A61L 27/3834 Cells able to produce different cell types, e.g. hematopoietic stem cells, mesenchymal stem cells, marrow stromal cells, embryonic stem cells
• CPC Class Codes: A61L 27/3886 comprising two or more cell types
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: C12N 2506/1384 from adipose-derived stem cells [ADSC], from adipose stromal stem cells
• CPC Class Codes: C12N 5/0667 Adipose-derived stem cells [ADSC]; Adipose stromal stem cells
• CPC Class Codes: C12N 5/069 Vascular Endothelial cells

Abstract

Cells present in adipose tissue are used to treat patients, including patients with PVD and related diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of stem cells obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, cells present in adipose tissue are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic benefit.

Claims

1. A method for treating peripheral vascular disease (PVD) in a patient, comprising administering to the patient by injection a concentration of regenerative cells.

2. The method of claim 1, wherein the subject is human.

3. The method of claim 1, wherein the regenerative cells are comprised of stem cells.

4. The method of claim 1, wherein the regenerative cells are comprised of progenitor cells.

5. The method of claim 1, wherein the regenerative cells are comprised of a combination of stem cells and progenitor cells.

6. The method of claim 1, wherein the regenerative cells are administered to treat a defect or disorder of a blood vessel.

7. The method of claim 1, wherein the regenerative cells are administered to treat Peripheral Artery Disease (PAD).

8. The method of claim 1, wherein the regenerative cells are administered to treat at least one of arteriosclerosis, traumatic injury of vessels and inflammatory arteritides.

9. The method of claim 1, wherein the regenerative cells are administered to treat a defect or disorder of extracoronary tissue of the patient.

10. The method of claim 1, wherein the method comprises administering a bolus of the regenerative cells.

11. The method of claim 1, wherein the method comprises administering multiple doses of the regenerative cells.

12. The method of claim 1, wherein the method further comprises administering one or more angiogenic factors.

13. The method of claim 1, wherein the wherein the method further comprises administering one or more immunosuppressive drugs.

14. The method of claim 1, wherein the regenerative cells are administered via at least one of an intravenous, intra-muscular or subcutaneous administration route.

15. The method of claim 1, wherein the method further comprises administering the regenerative cells to the patient'"'"'s vasculature.

16. The method of claim 1, wherein the regenerative cells are grown in cell culture prior to being administered to the patient.

17. The method of claim 15, wherein the regenerative cells are grown in culture conditions that promote differentiation towards an angiogenic phenotype.

18. The method of claim 15, wherein the cell culture conditions promote differentiation towards an endothelial phenotype.

19. The method of claim 15, wherein the cell culture is performed on a scaffold material to generate a two or three dimensional construct that can be placed on or within the patient.

20. The method of claim 18, wherein the scaffold material is resorbable in vivo.

21. The method of claim 1, wherein the regenerative cells are modified by gene transfer such that expression of one or more genes in the modified regenerative cells is altered.

22. The method of claim 21, wherein the modification results in alteration of the level of angiogenesis in the subject.

23. The method of claim 21, wherein the modification results in an improved oxygen supply of pre-existent small blood vessels in the subject.

24. The method of claim 21, wherein the modification results in alteration of the homing properties of the regenerative cells.

25. A method for treating PVD in a patient, comprising administering to the patient by injection a concentration of adipose tissue derived regenerative cells, wherein the composition is administered to the same subject from which the adipose tissue was originally harvested.

26. A method for promoting blood vessel growth in a patient comprising contacting by injection a localized area of tissue with a concentration of regenerative cells such that blood vessel growth within the area of tissue is induced.